In cancer immunotherapy, TNF-α is mainly considered as a mediator of anti-tumour immune responses, and several immunotherapies have shown depleted anti-tumour efficacy when co-administered with TNF-α antagonists.93,94 It is likely that acute immune responses are boosted by TNF-α release. This evidence concerns the gene TNF and neoplasm.